CytoDyn announced dosing of the first patient in its Phase 2a SALIENT-AD trial of Leronlimab for Alzheimer's disease. The update marks a clinical development milestone for the oncology company as it expands into neurodegenerative disease. The news is positive but routine for a biotech trial update and is unlikely to have a large immediate market impact.
CytoDyn announced dosing of the first patient in its Phase 2a SALIENT-AD trial of Leronlimab for Alzheimer's disease. The update marks a clinical development milestone for the oncology company as it expands into neurodegenerative disease. The news is positive but routine for a biotech trial update and is unlikely to have a large immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
